Regulation of the Cdk inhibitor p27 and its deregulation in cancer

Journal of Cellular Physiology

Volumn 183, Issue 1, 2000, Pages 10-17

  Slingerland, J ^a,b,c   Pagano, M ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REGULATORY MECHANISM;

ANIMALS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HOMEOSTASIS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0034092911     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I     Document Type: Article

References (106)

1. Kip1. Mol Cell Biol 17:3850-3857.
2. Alessandrini A, Chiaur DS, Erikson R, Pagano M. 1997. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345.
3. Assoian RK. 1997. Anchorage-dependent cell cycle progression. J Cell Biol 136:1-3.
4. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-Box. Cell 86:263-274.
5. Bouchard C, Thisted K, Maier A, Saffrich R, Henley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. 1999. Direct induction of cyclin D2 by Myc contributes to cell cycle induction and sequestration of p27. EMBO J 18:5321-5333.
6. Brandeis M, Hunt T. 1996. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J 15:5280-5289.
7. Carrano A, Eytan E, Hershko A, Pagano M. 1999. Skp2 is required for the ubiquitin-mediated degradation of the Cdk-inhibitor p27. Nat Cell Biol 1:193-199.
8. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230.
9. Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Cancer Res 59:684-688.
10. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. 1999. Identification of a human family of F-box proteins. Curr Biol 9:1177-1179.
11. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. 1996. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7:1571-1578.
12. Cheng M, Sexl V, Sherr CJ, Roussel MF. 1998. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 95:1091-1096.
13. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. 1999. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571-1583.
14. Chiarle R, Budel L, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, DeWolf C, Inghirani G. 1999. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood (in press).
15. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB. 1998. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58:114-122.
16. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. 1998. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90:916-920.
17. Durand B, Gao FB, Raff M. 1997. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 16:306-317.
18. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. 1998. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood 92:770-777.
19. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. 1997. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385.
20. Fan GK, Fujieda S, Sunaga H, Tsuzuki H, Ito N, Saito H. 1999. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope 109:815-820.
21. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Polyak K, Firpo E, Tsai L, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. 1996. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 85:733-744.
22. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. 1998. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
23. Florenes VA, Bhattacharya N, Bani MR, Ben-David J, Kerbel RS, Slingerland JM. 1996. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1 and p27Kip1. Oncogene 13:2447-2547.
24. Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 153:305-312.
25. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X. 1997. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385.
26. Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3:2269-2274.
27. Hartwell L. 1992. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546.
28. Hengst L, Reed SI. 1996. Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864.
29. Hengst L, Dulic V, Slingerland J, Lees E, Reed SI. 1994. A cell cycle regulated inhibitor of cyclin dependent kinases. Proc Natl Acad Sci USA 91:5291-5294.
30. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M. 1999. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30:90-99.
31. KIp1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 152:1-6.
32. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y. 1997. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637.
33. Kip1 in human malignancies. Cancer Res 55:2266-2269.
34. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. 1996. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721-732.
35. Koepp DM, Harper JW, Elledge SJ. 1999. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97:431-434.
36. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260:536-539.
37. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87:1069-1078.
38. Kumar A, Paietta JV. 1998. An additional role for the F-box motif: gene regulation within the Neurospora crassa sulfur control network. Proc Natl Acad Sci USA 95:2417-2422.
39. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
40. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. 1997. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F [published erratum appears in Nature 387(6636):932, 1997]. Nature 387:422-426.
41. Lloyd RV, Jin L, Qian X, Kulig E. 1997. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407.
42. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.
43. Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G. 1999. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18:2557-2566.
44. Mal A, Poon R, Howe P, Toyoshima H, Hunter T, Harter M. 1996. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGF-β treated cells. Nature 380:262-265.
45. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A. 1999. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer [in process citation]. Cancer Res 59:3790-3794.
46. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. 1997. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 272:7093-7098.
47. Mineta H, Miura K, Suzuki I, Takebayashi S, Amano H, Araki K, Harada H, Ichimura K, Wennerberg JP, Dictor MR. 1999. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85:1011-1017.
48. Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T. 1999. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 5:551-557.
49. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189.
50. Morgan DO. 1995. Principles of Cdk regulation. Nature 374:131-134.
51. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. 1997. p27 expression and gastric carcinoma. Nat Med 3:593.
52. Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M. 1997. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15:2561-2576.
53. Murray AW. 1992. Creative blocks: cell cycle checkpoints and feedback controls. Nature 359:599-604.
54. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K-E. 1996. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
55. Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S. 1998. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11:1165-1170.
56. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL. 1999. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154:119-125.
57. Nguyen H, Gitig DM, Koff A. 1999. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 19:1190-1201.
58. Orend G, Hunter T, Ruoslahti E. 1998. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 16:2575-2583.
59. Pagano M. 1997. Cell cycle regulation by the ubiquitin pathway. FASEB J 11:1067-1075.
60. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
61. Palmqvist R, Stenling R, Oberg A, Landberg G. 1999. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 188:18-23.
62. Patton EE, Willems AR, Tyers M. 1998. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet 14:236-243.
63. Perez-Roger I, Kim SH, Griffiths B, Sweing A, Land H. 1999. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21 Cip1. EMBO J 18:5310-5320.
64. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210.
65. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D. 1997. p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234:127-130.
66. Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D. 1999. Proteasome-dependent degradation of p27/kip1 in gliomas. J Neuropathol Exp Neurol 58:691-696.
67. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. 1994. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
68. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res 55:1211-1214.
69. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. 1997. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225.
70. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S. 1997 Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 272:13937-13944.
71. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J. 1994. G1 control in mammalian cells. J Cell Sci Suppl 18:69-73.
72. Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O. 1998. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 11:735-739.
73. Rivard N, L'Allemain G, Bartek J, Pouyssegur J. 1996. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem 271:18337-18341.
74. Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol MM, Sanchez-Verde L, Villuendas R, Troncone G, Piris MA. 1997. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151:151-160.
75. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, Piris MA. 1999. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94:765-772.
76. INK4B-cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. Mol Cell Biol 17:2458-2467.
77. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. 1997. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11:1464-1478.
78. Sherr CJ. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
79. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163.
80. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
81. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. 1999. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 274:13886-13893.
82. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58:1730-1735.
83. Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MR, Reed SI. 1994. A novel inhibitor of cyclin-Cdk activity detected in Transforming Growth Factor β-arrested epithelial cells. Mol Cell Biol 14:3683-3694.
84. St. Croix B, Florenes V, Rak A, Flanagan JW, Bhattacharya N, Slingerland JM, Kerbel RS. 1996. Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat Med 2:1204-1210.
85. Sutterlüty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. 1999. p45 SKP2 promotes p27 Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol 1:207-214.
86. Takuwa N, Takuwa Y. 1997. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 17:5348-5358.
87. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. 1997. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 57:1259-1263.
88. Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 [see comments]. Nature 398:160-165.
89. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548.
90. Tsihlias J, Kapusta L, Slingerland J. 1999. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50:401-423.
91. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. 1999. p27(Kip1) ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated thr187 in p27 [In Process Citation]. Curr Biol 9:661-664.
92. Ui M, Okada T, Hazeki K, Hazeki O. 1995. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem Sci 20:303-307.
93. Venkatesan TK, Kuropkat C, Caldarelli DD, Panje WR, Hutchinson JCJ, Chen S, Coon JS. 1999. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx [in process citation]. Laryngoscope 109:1329-1333.
94. Kip1 is abrogated by c-Myc. EMBO J 15:6595-6604.
95. Kip1. EMBO J 16:5334-5344.
96. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
97. Wang QM, Jones JB, Studzinski GP. 1996. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL-60 cells. Cancer Res 56:264-267.
98. Watanabe N, Hunter T, Ruoslahti E. 1996. Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science 271:499-502.
99. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. 1999. A family of mammalian F-box proteins. Curr Biol 9:1180-1182.
100. Yang RM, Naitoh J, Murphy M, Wang H-J, Philipson J, deKernion JB, Loda M, Reiter RE. 1998. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-945.
101. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. 1997. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88:625-629.
102. Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 58:1042-1047.
103. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. 1996. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13: 2323-2330.
104. Zhang H, Hannon G, Beach D. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758.
105. Zhang H, Kobayashi R, Galaktionov K, Beach D. 1995. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CKK2 S phase kinase. Cell 82:915-925.
106. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. 1996. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133:391-403.